To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-based conjoint (ACBC) module in the survey. Following appropriate analysis, ACBC data allow for the simulation of physician preference share and likelihood to prescribe of user-defined target product profiles (TPPs). Conjoint analysis is based on the idea that any product or service is seen by consumers as a combination of attributes or features, each of which contributes to their overall interest in the product or service.

We report on key ACBC analysis findings and one market simulation performed on three hypothetical TPPs (see the “Conjoint Analysis-Based Simulation of a Market Scenario”). The Excel-based Target Product Profile Simulator allows for the creation of up to seven user-defined TPPs with varying performance across the attributes included in the survey. To access the Excel-based Target Product Profile Simulator, see the “Downloads” section of the report.

Through research conducted by Decision Resources Group, we identified six attributes relevant to the assessment of biosimilar development opportunities in the oncology space to be included in our analysis. We included attributes for which are known to be key differentiators of biosimilars in the oncology space, including price:

  • Availability of clinical data in the indication I am prescribing for.
  • Inclusion in treatment guidelines.
  • Type of manufacturer.
  • Reimbursement restrictions.
  • Postmarketing data (time on market).
  • List price.

To select clinical attributes for our conjoint analysis, we considered insight from surveyed clinicians on key clinical and commercial factors influencing biosimilar prescribing choice as well as regulatory guidance on biosimilar development. Surveyed physicians' perception of the efficacy and safety of a biosimilar compared with its reference brand are key factors influencing its uptake. We included attributes that inform the type of clinical data available at launch, which can range from none (i.e., indication extrapolation) to full Phase III data, as well as the duration of postmarketing data. External factors (e.g., market access) also influence biosimilar prescribing choice; here, we included attributes that capture inclusion in local or national treatment guidelines and general payer policy. Surveyed physicians reported that trust in a biosimilar, and therefore prescribing comfort and choice, is influenced by manufacturer type; for this attribute, we included all key developer types evident in the global pipeline, ranging from large multinational biopharmaceutical companies to companies in emerging markets. Unsurprisingly, cost is the central driving factor that influences biosimilar uptake; here, we allowed for a range of list price discounts up to 50% relative to the reference brand.

Table of contents

  • Biosimilars - Current Treatment - Biosimilar Target Product Profiles (Oncology)
    • Target Product Profiles
      • Assessing Biosimilar Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Oncology Biosimilars Target Product Profile: Attribute Importance
        • Availability of Clinical Data in the Indication for Which I Am Prescribing
        • Inclusion in Treatment Guidelines
        • Type of Manufacturer
        • Reimbursement Restrictions
        • Postmarketing Data (time on market)
        • List Price
      • Conjoint Analysis-Based Simulation of a Market Scenario
        • Oncology Biosimilars Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
        • Oncology Biosimilars Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
        • Oncology Biosimilars Market Simulation: Target Product Profiles Included in the Market Scenario

Author(s): Neela Rambaruth

Neela Rambaruth is a Business Insights Analyst in the Oncology division at DRG. Neela joined DRG in 2018 and has since authored the Disease Landscape and Forecast report for non-small-cell lung cancer. Neela is currently working on the Disease Landscape and Forecast report for Hepatocellular carcinoma and the survey for Immune checkpoint US Access and Reimbursement.

Prior to joining DRG, Neela Rambaruth was a Postdoctoral Scientist at University College London, where she investigated the interaction of novel drugs with a therapeutic receptor involved in cardiovascular disease.  She also held another postdoctoral position at Imperial College London, where she studied host-pathogen interaction in tuberculosis. Dr Rambaruth holds a PhD in Breast Oncology from the University of Westminster.  Her doctorate focused on the identification of novel biomarkers associated with metastatic breast cancer. She has also published several peer-reviewed articles in oncology and therapeutic drug discovery.

Related Reports

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological...

View Details

Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diur...

View Details

Heart Failure | Disease Landscape and Forecast | G7 | 2020

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates...

View Details